

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/559,982
				Filing Date	February 2, 2006
				First Named Inventor	Ruggero FARIELLO
				Group Art Unit	1627
				Examiner Name	Sahar JAVANMARD
				Confirmation No.	6583
Sheet	1	of	1	Attorney Docket No.	373987-011US (102895)

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			Translation ²
					Yes No
	C117	Macleod <i>et al.</i> , "Monoamine oxidase B inhibitors for early Parkinson's disease (review)," <i>Cochrane Database of Systematic Reviews</i> 2005, Issue 3, Art. No.: CD004898. (Exhibit A to 3 rd Declaration of C. Warren Olanow)			
	C118	Stocchi <i>et al.</i> , "Initiating Levodopa/Carbidopa Therapy With and Without Entacapone in Early Parkinson Disease: The STRIDE-PD Study," <i>Ann. Neurol.</i> 68:18-27 (2010). (Exhibit B to 3 rd Declaration of C. Warren Olanow)			
	C119	Olanow, "Levodopa/Dopamine Replacement Strategies in Parkinson's Disease — Future Directions," <i>Mov. Disord.</i> 23(Suppl. 3): S613-S622 (2008). (Exhibit C to 3 rd Declaration of C. Warren Olanow)			
	C120	Olanow <i>et al.</i> , "Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications," <i>Lancet Neurology</i> 5:677-687 (2006). (Exhibit D to 3 rd Declaration of C. Warren Olanow)			
	C121	Lang <i>et al.</i> , "Progress In Clinical Neurosciences: A Forum on the Early Management of Parkinson's Disease," <i>Canadian J. Neurol. Sci.</i> 32:277-286 (2005). (Exhibit E to 3 rd Declaration of C. Warren Olanow)			
	C122	Newron Pharmaceuticals SpA, "Safinamide: Study 018 Top-Line Results," Investor and Analyst Call Presentation, November 4, 2010 (available online at http://www.newron.com) ("Study 018 Presentation"). (Exhibit F to 3 rd Declaration of C. Warren Olanow)			
	C123	Olanow <i>et al.</i> , "Parkinson's Disease And Other Movement Disorders," Chapter 372, in Harrison's Principles of Internal Medicine, 18th ed. (in press) (manuscript). (Exhibit G to 3 rd Declaration of C. Warren Olanow)			
	C124	Hely <i>et al.</i> , "The Sydney Multicenter Study of Parkinson's disease: The Inevitability of Dementia at 20 years," <i>Mov. Disord.</i> 6:837-844 (2008). (Exhibit H to 3 rd Declaration of C. Warren Olanow)			

16227509.1.BUSINESS

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered
Include copy of this form with next communication to applicant

¹ Unique citation designation number ² Applicant is to place a check mark here if English language Translation or translation of abstract is attached